AU2018317372B2 - Novel nicotine-binding antibodies - Google Patents

Novel nicotine-binding antibodies Download PDF

Info

Publication number
AU2018317372B2
AU2018317372B2 AU2018317372A AU2018317372A AU2018317372B2 AU 2018317372 B2 AU2018317372 B2 AU 2018317372B2 AU 2018317372 A AU2018317372 A AU 2018317372A AU 2018317372 A AU2018317372 A AU 2018317372A AU 2018317372 B2 AU2018317372 B2 AU 2018317372B2
Authority
AU
Australia
Prior art keywords
nicotine
seq
sequence
heavy
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018317372A
Other languages
English (en)
Other versions
AU2018317372A1 (en
Inventor
Nicola Beltraminelli
Zuzana Biesova
Stéphanie FALLOT
Steve Fuller
Matthew W. Kalnik
Mark G. LESAGE
Paul PENTEL
Thomas Thisted
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blink Biomedical SAS
Hennepin Healthcare Research Institute
Antidote Therapeutics Inc
Original Assignee
Blink Biomedical SAS
Hennepin Healthcare Res Institute
Antidote Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blink Biomedical SAS, Hennepin Healthcare Res Institute, Antidote Therapeutics Inc filed Critical Blink Biomedical SAS
Publication of AU2018317372A1 publication Critical patent/AU2018317372A1/en
Assigned to BLINK BIOMEDICAL SAS, Antidote Therapeutics, Inc., Hennepin Healthcare Research Institute reassignment BLINK BIOMEDICAL SAS Amend patent request/document other than specification (104) Assignors: Antidote Therapeutics, Inc., BliNK Biomedical, Hennepin Healthcare Research Institute
Application granted granted Critical
Publication of AU2018317372B2 publication Critical patent/AU2018317372B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2018317372A 2017-08-15 2018-08-14 Novel nicotine-binding antibodies Active AU2018317372B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545696P 2017-08-15 2017-08-15
US62/545,696 2017-08-15
PCT/US2018/046621 WO2019036419A1 (en) 2017-08-15 2018-08-14 NEW NICOTINE BINDING ANTIBODIES

Publications (2)

Publication Number Publication Date
AU2018317372A1 AU2018317372A1 (en) 2020-03-05
AU2018317372B2 true AU2018317372B2 (en) 2025-06-26

Family

ID=63405495

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018317372A Active AU2018317372B2 (en) 2017-08-15 2018-08-14 Novel nicotine-binding antibodies

Country Status (11)

Country Link
US (2) US11440970B2 (https=)
EP (2) EP4624496A3 (https=)
JP (1) JP7364555B2 (https=)
KR (1) KR102712005B1 (https=)
CN (1) CN111432883B (https=)
AU (1) AU2018317372B2 (https=)
BR (1) BR112020002994A2 (https=)
CA (1) CA3072767A1 (https=)
ES (1) ES3041362T3 (https=)
MX (1) MX2020001725A (https=)
WO (1) WO2019036419A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801594A1 (en) * 2018-06-06 2021-04-14 Antidote Therapeutics, Inc. Methods for improving circulation and treating cardiovascular disease
KR102530111B1 (ko) * 2022-03-11 2023-05-10 앱클론(주) 코티닌을 표적하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이들의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194158A2 (en) * 1985-03-08 1986-09-10 Baylor College of Medicine Anti-nicotine and anti-cotinine antibodies (monoclonal and other), and their uses in nicotine and cotinine assays

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002058635A2 (en) 2001-01-26 2002-08-01 The Scripps Research Institute Nicotine immunogens and antibodies and uses thereof
US20050089524A1 (en) 2002-03-01 2005-04-28 Sanderson Sam D. Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US20060111271A1 (en) 2004-11-24 2006-05-25 Cerny Erich H Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements
US8316104B2 (en) * 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
EP1963308A4 (en) 2005-11-28 2010-12-15 Nabi Biopharmaceuticals METHOD FOR PRODUCING A NICOTINE HAPTEN
WO2007100755A1 (en) 2006-02-27 2007-09-07 Nabi Biopharmaceuticals Method for decreasing the toxic effects of nicotine on fetuses in pregnant women
EP2065398A1 (en) 2007-11-29 2009-06-03 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
EP2222702B1 (en) * 2007-11-29 2016-01-13 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
JP2011524521A (ja) 2008-06-13 2011-09-01 ナビ バイオファーマシューティカルズ 喫煙停止キットおよび方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194158A2 (en) * 1985-03-08 1986-09-10 Baylor College of Medicine Anti-nicotine and anti-cotinine antibodies (monoclonal and other), and their uses in nicotine and cotinine assays

Also Published As

Publication number Publication date
KR20200089255A (ko) 2020-07-24
CN111432883B (zh) 2024-10-01
WO2019036419A1 (en) 2019-02-21
EP3668598A1 (en) 2020-06-24
EP3668598B1 (en) 2025-07-30
US20230089068A1 (en) 2023-03-23
AU2018317372A1 (en) 2020-03-05
US11440970B2 (en) 2022-09-13
ES3041362T3 (en) 2025-11-11
EP4624496A3 (en) 2025-12-17
US20200377616A1 (en) 2020-12-03
BR112020002994A2 (pt) 2020-08-11
MX2020001725A (es) 2020-08-20
KR102712005B1 (ko) 2024-09-30
JP2020531480A (ja) 2020-11-05
CA3072767A1 (en) 2019-02-21
JP7364555B2 (ja) 2023-10-18
CN111432883A (zh) 2020-07-17
EP4624496A2 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
ES2974803T3 (es) Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de la calcitonina y métodos para utilizarlos
De Villiers et al. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell
Treweek et al. An antidote for acute cocaine toxicity
CN109952314A (zh) 治疗难治性偏头痛
BR112014003679B1 (pt) Domínio variável de imunoglobulina único, composição farmacêutica, formulação, ácido nucleico isolado ou recombinante, vetor, microorganismo transgênico, e, uso de uma composição farmacêutica
LeSage et al. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies
US20230089068A1 (en) Novel nicotine-binding antibodies
RS59354B1 (sr) Postupci lečenja nosne polipoze davanjem il-4r antagonista
Raleigh et al. Attenuating nicotine’s effects with high affinity human anti-nicotine monoclonal antibodies
KR20230030573A (ko) 항-bet v1 항체를 사용하여 알러지를 치료하는 방법
CA2895702C (en) Heroin haptens, immunoconjugates and related uses
Pentel et al. Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats
Chapman et al. Substructure-specific antibodies against fentanyl derivatives
CN113474363A (zh) 用于降低体重和/或减少食物摄取量的gdf15类似物和方法
US20220267474A1 (en) Methods for improving circulation and treating cardiovascular disease
JP2023550672A (ja) ポリオーマウイルス中和抗体の投薬
Pashmi Immunotherapy approach to combat nicotine addiction
KR20260057440A (ko) 항-cd203c 항체 접합체 및 이의 용도
CN117120092A (zh) 用于治疗儿科重症肌无力的组合物和方法
HK40067775A (en) Dosing for anti-tryptase antibodies
HK40008538A (zh) 治疗难治性偏头痛
Roiko Passive immunization to treat nicotine dependence in rats
Cornish Enhancing the efficacy of a nicotine vaccine
Pentel Hennepin County Medical Center and University of Minnesota
Oliver Vaccination against cotinine as a potential approach to smoking cessation

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ANTIDOTE THERAPEUTICS, INC.

Free format text: FORMER NAME(S): BLINK BIOMEDICAL; ANTIDOTE THERAPEUTICS, INC.; HENNEPIN HEALTHCARE RESEARCH INSTITUTE

Owner name: HENNEPIN HEALTHCARE RESEARCH INSTITUTE

Free format text: FORMER NAME(S): BLINK BIOMEDICAL; ANTIDOTE THERAPEUTICS, INC.; HENNEPIN HEALTHCARE RESEARCH INSTITUTE

Owner name: BLINK BIOMEDICAL SAS

Free format text: FORMER NAME(S): BLINK BIOMEDICAL; ANTIDOTE THERAPEUTICS, INC.; HENNEPIN HEALTHCARE RESEARCH INSTITUTE

FGA Letters patent sealed or granted (standard patent)